Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vir Biotechnology Inc
(NQ:
VIR
)
8.260
-0.040 (-0.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vir Biotechnology Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Breaking Down Vir Biotechnology: 6 Analysts Share Their Views
August 02, 2024
Via
Benzinga
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
August 01, 2024
VIR stock results show that Vir Biotechnology missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
July 26, 2024
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Via
Investor's Business Daily
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
July 04, 2024
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.
Via
InvestorPlace
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
June 05, 2024
Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran.
Via
Benzinga
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
June 05, 2024
Via
Benzinga
Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
May 24, 2024
Via
Benzinga
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
June 05, 2024
Via
Benzinga
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
May 07, 2024
Via
Benzinga
VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024
May 02, 2024
VIR stock results show that Vir Biotechnology beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
March 15, 2024
Via
Benzinga
Recap: Vir Biotechnology Q4 Earnings
February 22, 2024
Via
Benzinga
Earnings Outlook For Vir Biotechnology
February 21, 2024
Via
Benzinga
JP Morgan Downgrades Vir Biotechnology: Here's What You Need To Know
January 29, 2024
Via
Benzinga
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
March 19, 2024
These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations.
Via
InvestorPlace
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via
InvestorPlace
3 Highly Rated Biotech Stocks to Buy for 300% Gains
February 26, 2024
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.
Via
InvestorPlace
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
February 23, 2024
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 23, 2024
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results.
Via
Benzinga
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
February 14, 2024
Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation.
Via
InvestorPlace
HC Wainwright & Co. Maintains Buy Rating for Vir Biotechnology: Here's What You Need To Know
January 23, 2024
Via
Benzinga
Earnings Scheduled For February 22, 2024
February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
Via
Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
December 20, 2023
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n
Via
Benzinga
Exposures
COVID-19
7 Small-Cap Stocks to Buy BEFORE the Year-End Rally
November 30, 2023
explore and wager on these top small-cap stocks to buy, poised for significant gains in today's dynamic global economy
Via
InvestorPlace
3 Bill Gates Stocks to Buy for Billionaire-Like Returns
October 27, 2023
Microsoft and Berkshire Hathaway are the two most popular Bill Gates stocks. Investors know these three others far less.
Via
InvestorPlace
7 Biotech Stocks to Get In Now Before Investors Catch On
October 23, 2023
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.
Via
InvestorPlace
Earnings Scheduled For November 2, 2023
November 02, 2023
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Via
Benzinga
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
September 27, 2023
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria. More than a million people worldwide succumb to infections caused...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 21, 2023
During the session on Thursday, 461 stocks hit new 52-week lows.
Via
Benzinga
Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades
September 08, 2023
BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14,
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.